



THE COURSE SCHEDULE OF LECTURES
of **Clinical Pharmacy and Pharmaceutical Care** for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program **Pharmacy**
4 years 10 months of study, Language of Instruction — English,
groups **ФМ19(4,10Д)АНГЛ-01, 02, 03, 04 ,05, 06, 07, 08**
(spring semester, 2022-2023, module 1)

№	Date	Topic	Hour	Lecturer
MODULE 1				
1.	19/01/23	Introduction in Clinical Pharmacy. Clinical Pharmacy in Pulmonology	1	Ass. prof. I.A.Otrishko
2.	26/01/23	Clinical Pharmacy in Pulmonology	1	Ass. prof. I.A.Otrishko
3.	02/02/23	Clinical Pharmacy in Rheumatology	1	Ass. prof. I.A.Otrishko
4.	09/02/23	Clinical Pharmacy in Rheumatology	1	Ass. prof. I.A.Otrishko
5.	16/02/23	Clinical Pharmacy in Cardiology	1	Ass. prof. I.A.Otrishko
6.	23/02/23	Clinical Pharmacy in Cardiology	1	Ass. prof. I.A.Otrishko
7.	02/03/23	Clinical Pharmacy in Cardiology	1	Ass. prof. I.A.Otrishko
8.	16/03/23	Clinical Pharmacy in Haematology	1	Ass. prof. I.A.Otrishko
9.	23/03/23	Clinical Pharmacy in Nephrology	1	Ass. prof. I.A.Otrishko
10.	30/03/23	Clinical Pharmacy in Nephrology	1	Ass. prof. I.A.Otrishko
11.	06/04/23	Clinical Pharmacy in Gastroenterology	1	Ass. prof. I.A.Otrishko
12.	13/04/23	Clinical Pharmacy in Gastroenterology	1	Ass. prof. I.A.Otrishko
13.	20/04/23	Clinical Pharmacy in Hepatology	1	Ass. prof. I.A.Otrishko
14.	27/04/23	Clinical Pharmacy in Hepatology	1	Ass. prof. I.A.Otrishko
15.	04/05/23	Clinical Pharmacy in Endocrinology	1	Ass. prof. I.A.Otrishko
16.	11/05/23	Clinical Pharmacy in Endocrinology	1	Ass. prof. I.A.Otrishko
17.	18/05/23	Clinical Pharmacy in Allergy Pharmaceutical Care: Basic Definitions	1 1	Ass. prof. I.A.Otrishko
Total:			18	

Note: the lecture is delivered on Thursday at 11.20-12.05 as online ZOOM-conference

clinpharm.nuph.edu.ua/en/for-students

Acting Head of Department of Clinical Pharmacology
and Clinical Pharmacy, Professor

_____ Tetiana SAKHAROVA



THE COURSE SCHEDULE OF PRACTICAL CLASSES
of **Clinical Pharmacy and Pharmaceutical Care** for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program **Pharmacy**,
4 years 10 months of study, Language of Instruction — English,
groups **ФМ19(4,10Д.)АНГЛ-01, 02, 03, 04, 05, 06, 07, 08**
(spring semester, 2022-2023, module 1)

№	Date	Topic	Hours, type of classes	Points	
				min	max
MODULE 1. CONTENT MODULE 1. The basic principles of clinical pharmacy and clinical pharmacology. Clinical pharmacy in pulmonology, rheumatology, cardiology, hematology					
1.	16.01.23 - 06,07,08 18.01.23 - 01,02 19.01.23 - 03,04 20.01.23 - 05	Basic concepts of clinical pharmacy. Methods of examination of a patient. Symptoms and syndromes in internal medicine	3, <i>Pr.Cl.</i>	1,5	2,5
2.	23.01.23 - 06,07,08 25.01.23 - 01,02 26.01.23 - 03,04 27.01.23 - 05	Basic principles of clinical pharmacology. Clinical aspects of pharmacodynamics and pharmacokinetics. Types of drug interactions. Adverse drug reactions. Clinical study of drugs	3, <i>Pr.Cl.</i>	1,5	2,5
3.	30.01.23 - 06,07,08 01.02.23 - 01,02 02.02.23 - 03,04 03.02.23 – 05	Clinical Pharmacy in Pulmonology. Symptoms and syndromes in pulmonology	3, <i>Pr.Cl.</i>	1,5	2,5
4.	06.02.23 - 06,07,08 08.02.23 - 01,02 09.02.23 - 03,04 10.02.23 – 05	Clinical Pharmacy in Pulmonology. Clinical pharmacology of drugs used to treat the respiratory system diseases: antibacterial drugs, bronchodilators, inhalation steroids	3, <i>Pr.Cl.</i>	1,5	2,5
5.	13.02.23 - 06,07,08 15.02.23 - 01,02 16.02.23 - 03,04 17.02.23 - 05	Clinical Pharmacy in Rheumatology. Symptoms and syndromes in rheumatology	3, <i>Pr.Cl.</i>	1,5	2,5
6.	20.02.23 - 06,07,08 22.02.23 - 01,02 23.02.23 - 03,04 24.02.23 – 05	Clinical Pharmacy in Rheumatology. Clinical pharmacology of drugs used to treat the systemic connective tissue diseases, rheumatism	3, <i>Pr.Cl.</i>	1,5	2,5
7.	27.02.23 - 06,07,08 01.03.23 - 01,02 02.03.23 - 03,04 03.03.23 – 05	Clinical Pharmacy in Cardiology. Symptoms and syndromes. Clinical pharmacology of drugs used to treat the atherosclerosis and ischemic heart disease	3, <i>Pr.Cl.</i>	3	5
8.	06.03.23 - 06,07,08 08.03.23 - 01,02 09.03.23 - 03,04 10.03.23 – 05	Clinical Pharmacy in Cardiology. Symptoms and syndromes. Clinical pharmacology of drugs used to treat the arterial hypertension and chronic heart failure	3, <i>Pr.Cl.</i>	3	5
9.	13.03.23 - 06,07,08 15.03.23 - 01,02 16.03.23 - 03,04 17.03.23 - 05	Clinical Pharmacy in Haematology. Symptoms and syndromes. Clinical pharmacology of drugs used to treat anaemia	3, <i>Pr.Cl.</i>	3	5
10.	20.03.23 - 06,07,08 22.03.23 - 01,02 23.03.23 - 03,04	<i>Control of Content module 1</i>	3, <i>Pr.Cl.</i>	12	20
	24.03.23 – 05	<i>Total for Content module 1:</i>		30	50

№	Date	Topic	Hours, type of classes	Points		
				min	max	
CONTENT MODULE 2. Clinical pharmacy in nephrology, gastroenterology, hepatology, endocrinology, allergology						
11.	27.03.23 - 06,07,08 29.03.23 - 01,02 30.03.23 - 03,04 31.03.23 – 05	Clinical Pharmacy in Nephrology. Symptoms and syndromes	3, <i>Pr.Cl.</i>	1,5	2,5	
12.	03.04.23 - 06,07,08 05.04.23 - 01,02 06.04.23 - 03,04 07.04.23 - 05	Clinical Pharmacy in Nephrology. Clinical pharmacology of drugs used to treat the infection diseases of the kidneys and urinary tract	3, <i>Pr.Cl.</i>	1,5	2,5	
13.	10.04.23 - 06,07,08 12.04.23 - 01,02 13.04.23 - 03,04 14.04.23 – 05	Clinical Pharmacy in Gastroenterology. Symptoms and syndromes	3, <i>Pr.Cl.</i>	1,5	2,5	
14.	17.04.23 - 06,07,08 19.04.23 - 01,02 20.04.23 - 03,04 21.04.23 – 05	Clinical Pharmacy in Gastroenterology. Clinical pharmacology of drugs used to treat the digestive system and pancreas diseases	3, <i>Pr.Cl.</i>	3	5	
15.	24.04.23 - 06,07,08 26.04.23 - 01,02 27.04.23 - 03,04 28.04.23 – 05	Clinical Pharmacy in Hepatology. Symptoms and syndromes	3, <i>Pr.Cl.</i>	1,5	2,5	
16.	01.05.23 - 06,07,08 03.05.23 - 01,02 04.05.23 - 03,04 05.05.23 – 05	Clinical Pharmacy in Hepatology. Clinical pharmacology of drugs used to treat the hepatobiliary system diseases	3, <i>Pr.Cl.</i>	1,5	2,5	
17.	08.05.23 - 06,07,08 10.05.23 - 01,02 11.05.23 - 03,04 12.05.23 – 05	Clinical Pharmacy in Endocrinology. Symptoms and syndromes of diabetes mellitus, toxic goiter, hypophysis and adrenal gland diseases	3, <i>Pr.Cl.</i>	1,5	2,5	
18.	15.05.23 - 06,07,08 17.05.23 - 01,02 18.05.23 - 03,04 19.05.23 – 05	Clinical Pharmacy in Endocrinology. Clinical pharmacology of drugs used to treat the endocrinal system diseases	3, <i>Pr.Cl.</i>	3	5	
19.	22.05.23 - 06,07,08 24.05.23 - 01,02 25.05.23 - 03,04 26.05.23 – 05	Clinical Pharmacy in Allergy. Symptoms and syndromes. Clinical pharmacology of antiallergic drugs	3, <i>Pr.Cl.</i>	3	5	
20.	29.05.23 - 06,07,08 31.05.23 - 01,02 01.06.23 - 03,04 02.06.23 - 05	Control of Content module 2	3, <i>Pr.Cl.</i>	12	20	
		Total for Content module 2:		30	50	
		Module 1 Ranking Upgrade				
		Credit				
TOTAL FOR MODULE 1			60	60	100	

Acting Head of Department of Clinical Pharmacology
and Clinical Pharmacy, Professor

Tetiana SAKHAROVA



THE TOPICS OF SELF-DIRECTED LEARNING
of Clinical Pharmacy and Pharmaceutical Care for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program Pharmacy,
4 years 10 months of study, Language of Instruction — English,
groups **ФМ19(4,10Д)АНГЛ-01, 02, 03, 04 ,05, 06, 07, 08**
(spring semester, 2022-2023, module 1)

№	Topic
1.	Principal aspects of medical documentation. Clinical pharmacological tests. Placebo-effectors. Negative placebo-effectors as a group of risk of adverse drug reaction development. The concept «quality of life» concerning patients with chronic diseases and disorders of general state
2.	Definition of «emphysema of lungs», «pleurisy», «bronchoectatic disease», «lung abscess». Clinical pharmacology of carbapenems. Modern special dosage forms used for treating the respiratory system diseases
3.	Definition of «systemic scleroderma». Bicillinoprophylaxis and bicillinotherapy. Clinical pharmacology of basic anti-inflammatory drugs (derivatives of quinoline, cytostatics, medicines of gold), including drugs suppressing proliferation of the connective tissue. Drugs affecting the structure and mineralization of the bone tissue
4.	Definition of «cardiosclerosis». Clinical pharmacology of drugs, which improve cerebral circulation; angioprotectors and antioxidants; drugs of metabolic action; non-glycosides of positive inotropic agents; antiarrhythmic drugs. Drugs having a negative effect on the safety of the cardiovascular system
5.	Definition of hemoblastosis (acute leukemia myeloleukemia, chronic lymphatic leukemia), erythremia. Clinical pharmacology of drugs, which stimulate or inhibit erythro- and leukopoiesis. Drugs which toxically affect the condition of hemopoietic system
6.	Chronic cystitis: definition, symptoms, syndroms, approaches to treatment. Symptomatic arterial hypertension (renoparenchymatous and renovascular one): definition, symptoms, syndroms, approaches to treatment. Clinical pharmacology of hypoosmotics
7.	Clinical pharmacology of drugs which increase tonus and stimulate motility of GIT (agonists of acetylcholine, antagonists of dopamine receptors), and antiemetic drugs. Drugs that have a toxic effect on condition of GIT and pancreas
8.	Chronic pancreatitis: symptoms, syndromes. Clinical pharmacology of polyezyme drugs
9.	Chronic cholecystitis: symptoms, syndromes, approaches to the treatment, clinical pharmacology of antibacterial drugs, criteria of efficiency and safety of chosen treatment
10.	Clinical pharmacology of drugs for treating viral and bacterial infections of the hepatobiliary system (interferons, nucleotide analogues; penicillins, tetracyclines, cephalosporins, fluoroquinolones). Clinical pharmacology of detoxication therapy agents (enterosorbents, combined infusion solutions)
11.	Endemic goiter, diabetic polyneuropathy, diabetic nephropathy: clinical manifestations, approaches to the treatment, clinical pharmacology of drugs, criteria of efficiency and safety of chosen treatment
12.	Syndromes of drug disease (Lyell's syndrome, Stevens-Johnson syndrome). Polypharmacy as the cause of medicinal therapy complications

Acting Head of Department of Clinical Pharmacology
and Clinical Pharmacy, Professor

Tetiana SAKHAROVA



QUESTIONS FOR CONTENT MODULE CONTROLS #1 AND #2
of Clinical Pharmacy and Pharmaceutical Care for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program Pharmacy,
4 years 10 months of study, Language of Instruction — English,
groups ФМ19(4,10Д)англ-01, 02, 03, 04 ,05, 06, 07, 08
(spring semester, 2022-2023, module 1)

1. Definition of the concepts of "chemical name", "international nonproprietary name", "trade name" of drugs.
 2. The factors affecting the clinical efficiency of drugs.
 3. Clinical and pharmacological characteristics of various ways of drug administration.
 4. Basic pharmacokinetic parameters, their practical importance. Visceral diseases that affect pharmacokinetic indices essentially.
 5. Anatomical and physiological peculiarities of the human body in different age periods (newborns, children, teenagers, elderly and old people), which have an effect on pharmacokinetics and pharmacodynamics of medicines.
 6. Anatomical and physiological peculiarities of the organism of a woman during pregnancy, which have an effect on pharmacokinetics and pharmacodynamics of medicines products.
 7. Medicinal monitoring. Factors, that cause the necessity of carrying out the medicinal monitoring.
 8. Bioavailability of drugs. The clinical importance of bioavailability. Factors affecting the bioavailability value.
 9. Bioequivalent drugs. Categories of drugs, which bioequivalence studies are conducted for.
 10. Bioequivalence. Clinical methods of bioequivalence determination. Therapeutic non-bioequivalence of drugs, its causes.
 11. Selectivity of drug action. Factors that have an effect on the selectivity of medicines.
 12. Brand drugs. Advantages of brands and disadvantages of generics.
 13. Generic drugs. Requirements for generics.
 14. Criteria of drug efficiency. Groups of the efficiency criteria.
 15. Criteria of drug safety. Groups of the safety criteria.
 16. Interaction of drugs. Types of interaction. Clinical importance of drug interaction.
 17. Pharmacodynamic and pharmacokinetic synergy. Possibilities of its use in clinical practice.
 18. Pharmacodynamic and pharmacokinetic antagonism. Ways of prevention of drug antagonism.
 19. Pharmaceutical interaction of drugs. Positive and negative sides.
 20. Combined drugs. Advantages and disadvantages of combined drugs.
 21. Types of adverse reactions and complications of medicinal therapy.
 22. Toxic complications caused by an absolute or relative overdose of drugs, pharmacological properties of drugs.
 23. Allergic reactions, idiosyncrasy, withdrawal syndrome as the manifestation of a adverse drug reactions.
 24. The concept of placebo, placebo – effectors. Negative placebo – effectors as a group of risk for developing adverse drug reactions.
 25. Effects of drugs on clinical and laboratory values and the results of functional tests. Possible mechanisms of action and the way of its prevention.
 26. Medicinal anamnesis. The importance of medicinal anamnesis collection for the rational therapy.
 27. Compliance. Major factors affecting on compliance.
 28. Phases of clinical approbation, goals and tasks of each stage.
-
29. Syndrome of bronchoobstruction, clinical manifestations.
 30. Syndrome of respiratory insufficiency, clinical manifestations.
 31. Symptoms and syndromes of pneumonia.
 32. Symptoms and syndromes of acute bronchitis.
 33. Symptoms and syndromes of chronic bronchitis.
 34. Symptoms and syndromes of chronic obstructive bronchitis.
 35. Symptoms and syndromes of bronchial asthma.
 36. Symptoms and syndromes of rheumatism (acute rheumatic fever, chronic rheumatic heart disease).
 37. Symptoms and syndromes of rheumatoid arthritis.
 38. Symptoms and syndromes of systemic lupus erythematosus.
 39. Symptoms and syndromes of osteoarthritis.
 40. Symptoms and syndromes of gout.
 41. Symptoms and syndromes of osteoporosis.
 42. Symptoms and syndromes of atherosclerosis.
 43. Symptoms and syndromes of stable angina.
 44. Symptoms and syndromes of acute myocardial infarction.
 45. Symptoms and syndromes of essential arterial hypertension
 46. Types of symptomatic arterial hypertension. Peculiarities of clinical manifestations.
 47. Differences of clinical symptomatology of hypertension disease of the Ist, IInd and IIId stages.
 48. Hypertension crisis. Differences of clinical symptomatology of hypertension crises of the Ist and IInd order.
 49. The basic symptoms of chronic cardiac failure.
 50. The basic symptoms of abnormalities of the heart rate.
 51. Symptoms and syndromes of iron deficiency anemia.

52. Symptoms and syndromes of megaloblastic (vitamin B12- and folic) anemia.
 53. Symptoms and syndromes of hemolytic anemia.
 54. Symptoms and syndromes of acute pyelonephritis.
 55. Symptoms and syndromes of chronic pyelonephritis.
 56. Symptoms and syndromes of acute glomerulonephritis.
 57. Symptoms and syndromes of chronic glomerulonephritis.
 58. Symptoms and syndromes of cystitis.
 59. Symptoms and syndromes of urolithiasis.
 60. Chronic renal failure, basic clinical manifestations.
 61. Symptoms and syndromes of chronic atrophic gastritis (type A).
 62. Symptoms and syndromes of chronic Helicobacter-associated gastritis (type B).
 63. Symptoms and syndromes of stomach ulcer.
 64. Symptoms and syndromes of duodenal ulcer.
 65. Symptoms and syndromes of chronic pancreatitis.
 66. Symptoms and syndromes of chronic hepatitis.
 67. Symptoms and syndromes of chronic cholecystitis.
 68. Syndrome of portal hypertension, basic clinical manifestations.
 69. Symptoms and syndromes of cirrhosis.
 70. Symptoms and syndromes of cholelithiasis.
 71. Symptoms and syndromes of diabetes mellitus.
 72. Symptoms and syndromes of diabetes mellitus (insulin-dependent diabetes mellitus).
 73. Diabetes complications, basic clinical manifestations.
 74. Symptoms and syndromes of hyperthyroidism.
 75. Symptoms and syndromes of hypothyroids.
 76. Symptoms and syndromes of endemic goiter.
 77. Symptoms and syndromes of allergic rhinitis and allergic conjunctivitis (pollinosis).
 78. Symptoms and syndromes of urticaria.
 79. Symptoms and syndromes of angioneurotic edema.
 80. Symptoms and syndromes of anaphylactic shock.
 81. Symptoms and syndromes of drug disease.
-
82. Clinical and pharmacological approaches to treatment of rheumatism (acute rheumatic fever, chronic rheumatic heart disease).
 83. Clinical and pharmacological approaches to treatment of rheumatoid arthritis.
 84. Clinical and pharmacological approaches to treatment of systemic lupus erythematosus.
 85. Clinical and pharmacological approaches to treatment of osteoarthritis.
 86. Clinical and pharmacological approaches to treatment of gout.
 87. Clinical and pharmacological approaches to treatment of osteoporosis.
 88. Clinical and pharmacological approaches to treatment of pneumonia.
 89. Clinical and pharmacological approaches to treatment of acute bronchitis.
 90. Clinical and pharmacological approaches to treatment of chronic bronchitis.
 91. Clinical and pharmacological approaches to treatment of chronic obstructive bronchitis.
 92. Clinical and pharmacological approaches to treatment of bronchial asthma.
 93. Clinical and pharmacological approaches to treatment of atherosclerosis.
 94. Clinical and pharmacological approaches to treatment of stable angina of effort.
 95. Clinical and pharmacological approaches to treatment of acute myocardial infarction.
 96. Clinical and pharmacological approaches to treatment essential arterial hypertension.
 97. Clinical and pharmacological approaches to treatment of symptomatic arterial hypertension.
 98. Clinical and pharmacological approaches to treatment of hypertensive crises of the Ist and IInd order.
 99. Clinical and pharmacological approaches to treatment of chronic heart failure.
 100. Clinical and pharmacological approaches to treatment of iron-deficiency anemia.
 101. Clinical and pharmacological approaches to treatment of megaloblastic (vitamin B12- and folic deficiency) anemia.
 102. Clinical and pharmacological approaches to treatment of acute pyelonephritis.
 103. Clinical and pharmacological approaches to treatment of chronic pyelonephritis.
 104. Clinical and pharmacological approaches to treatment of acute glomerulonephritis.
 105. Clinical and pharmacological approaches to treatment of chronic glomerulonephritis.
 106. Clinical and pharmacological approaches to treatment of cystitis.
 107. Clinical and pharmacological approaches to treatment of urolithiasis.
 108. Clinical and pharmacological approaches to treatment of chronic renal failure.
 109. Clinical and pharmacological approaches to treatment of chronic atrophic gastritis (type A).
 110. Clinical and pharmacological approaches to treatment of chronic Helicobacter-associated gastritis (type B).
 111. Clinical and pharmacological approaches to treatment of stomach ulcer.
 112. Clinical and pharmacological approaches to treatment of duodenal ulcer.
 113. Clinical and pharmacological approaches to treatment of chronic pancreatitis.
 114. Clinical and pharmacological approaches to treatment of chronic hepatitis.
 115. Clinical and pharmacological approaches to treatment of chronic cholecystitis.

116. Clinical and pharmacological approaches to treatment of portal hypertension.
 117. Clinical and pharmacological approaches to treatment of cirrhosis.
 118. Clinical and pharmacological approaches to treatment of cholelithiasis.
 119. Clinical and pharmacological approaches to treatment of diabetes mellitus type 1.
 120. Clinical and pharmacological approaches to treatment of diabetes mellitus type 2.
 121. Clinical and pharmacological approaches to treatment of complications of diabetes mellitus.
 122. Clinical and pharmacological approaches to treatment of hyperthyroidism.
 123. Clinical and pharmacological approaches to treatment of hypothyroidism.
 124. Clinical and pharmacological approaches to treatment of endemic goiter.
 125. Clinical and pharmacological approaches to treatment of allergic rhinitis and allergic conjunctivitis (pollinosis).
 126. Clinical and pharmacological approaches to treatment of urticaria.
 127. Clinical and pharmacological approaches to treatment of angioneurotic edema.
 128. Clinical and pharmacological approaches to treatment of allergic shock.
 129. Clinical and pharmacological approaches to treatment of drug disease.
-
130. Clinical pharmacology of steroid anti-inflammatory drugs.
 131. Clinical pharmacology of non-steroid anti-inflammatory drugs.
 132. Clinical pharmacology of basic anti-inflammatory drugs, including drugs that suppress proliferation of the connective tissue.
 133. Clinical pharmacology of metabolism correctors of the connective tissue.
 134. Clinical pharmacology of drugs of uricosuric action.
 135. Clinical pharmacology of drugs affecting the structure and mineralization of the bone tissue.
 136. Principles of the rational antibiotic therapy for organs of the respiratory system.
 137. Clinical pharmacology of bronchodilators.
 138. Clinical pharmacology of glucocorticosteroid inhalations.
 139. Clinical pharmacology of stabilizers of mastocytes membranes.
 140. Clinical pharmacology of expectorants and mucolytic agents.
 141. Clinical pharmacology of hypolipidemic drugs.
 142. Clinical pharmacology of antianginal drugs of nitrate group.
 143. Clinical pharmacology of β -adrenoblockers.
 144. Peculiarities of using β -adrenoblockers for IHD.
 145. Peculiarities of using β -adrenoblockers for arterial hypertension.
 146. Clinical pharmacology of calcium antagonists.
 147. Peculiarities of using calcium antagonists for IHD.
 148. Peculiarities of using calcium antagonists for arterial hypertension.
 149. Clinical pharmacology of ACE inhibitors.
 150. Peculiarities of using ACE inhibitors for arterial hypertension and chronic heart insufficiency.
 151. Clinical pharmacology of diuretics.
 152. Peculiarities of using diuretics in arterial hypertension and chronic heart failure.
 153. Clinical pharmacology of cardiac glycosides.
 154. Clinical pharmacology of anticoagulants and antiplatelets.
 155. Clinical pharmacology of iron drugs.
 156. Principles of the rational antibiotic therapy of diseases of the urinary system organs.
 157. Peculiarities of using immunosuppressants for treating immuno-inflammatory diseases of kidneys.
 158. The influence of the functional state of kidneys on clinical efficiency of drugs.
 159. Changes of pharmacodynamics and pharmacokinetics of drugs in case of chronic renal failure.
 160. AB therapy. Schemes of H. pylori eradication and clinical and pharmacological characteristic of drugs included in the given schemes.
 161. Clinical pharmacology of antacids.
 162. Clinical pharmacology of blockers of histamine H₂-receptor and selective M₁- blockers.
 163. Clinical pharmacology of proton pump inhibitors.
 164. Clinical pharmacology of anti-diarrhea drugs.
 165. Clinical pharmacology of laxatives.
 166. Action of the functional condition of the stomach on clinical efficiency of drugs.
 167. Clinical pharmacology of polyenzymatic drugs.
 168. Clinical pharmacology of cholagogic drugs.
 169. Clinical pharmacology of hepatoprotectors.
 170. Clinical pharmacology of drugs for etiotropic treatment of hepatic diseases.
 171. Changes of pharmacokinetics and pharmacodynamics of drugs in case of hepatic diseases.
 172. Action of the functional condition of the liver on clinical efficiency drugs.
 173. Clinical pharmacology of insulin drugs.
 174. Clinical pharmacology of oral hypoglycemic drugs.
 175. Clinical pharmacology of hormone drugs of the thyroid gland, anti-thyroid drugs, iodine drugs.
 176. Clinical pharmacology of antihistaminic drugs.
 177. Clinical pharmacology of topic antiallergic drugs.
-
178. Criteria of efficiency of pneumonia treatment and safety of medicinal therapy.

179. Criteria of efficiency of acute bronchitis treatment and safety of medicinal therapy.
180. Criteria of efficiency of chronic bronchitis treatment and safety of medicinal therapy.
181. Criteria of efficiency of treatment of chronic obstructive bronchitis and safety of medicinal therapy.
182. Criteria of efficiency of bronchial asthma treatment and safety of medicinal therapy.
183. Criteria of efficiency of rheumatism treatment (acute rheumatic fever, chronic rheumatic heart disease) and safety of medicinal therapy.
184. Criteria of efficiency of rheumatoid arthritis treatment and safety of medicinal therapy.
185. Criteria of efficiency of systemic lupus erythematosus treatment and safety of medicinal therapy.
186. Criteria of efficiency of osteoarthritis treatment and safety of medicinal therapy.
187. Criteria of efficiency of gout treatment and safety of medicinal therapy.
188. Criteria of efficiency of osteoporosis treatment and safety of medicinal therapy.
189. Criteria of efficiency of atherosclerosis treatment and safety of medicinal therapy.
190. Criteria of efficiency of treatment of stable angina of efforts and safety of medicinal therapy.
191. Criteria of efficiency of acute myocardial infarction treatment and safety of medicinal therapy.
192. Criteria of efficiency of essential arterial hypertension treatment and safety of medicinal therapy.
193. Criteria of efficiency of symptomatic arterial hypertension treatment and safety of medicinal therapy.
194. Criteria of efficiency of treatment of hypertension crises of the Ist and IInd order and safety of medicinal therapy.
195. Criteria of efficiency of treatment of chronic heart failure and safety of medicinal therapy.
196. Criteria of efficiency of treatment of iron deficiency anemia and safety of medicinal therapy.
197. Criteria of efficiency of treatment of megaloblastic (vitamin B12- and folic acid deficiency) anemia and safety of medicinal therapy.
198. Criteria of efficiency of acute pyelonephritis treatment and safety of medicinal therapy.
199. Criteria of efficiency of a chronic pyelonephritis treatment and safety of medicinal therapy.
200. Criteria of efficiency of acute glomerulonephritis treatment and safety of medicinal therapy.
201. Criteria of efficiency of chronic glomerulonephritis treatment and safety of medicinal therapy.
202. Criteria of efficiency of cystitis treatment and safety of medicinal therapy.
203. Criteria of efficiency of urolithiasis treatment and safety of medicinal therapy.
204. Criteria of efficiency of treatment of chronic renal failure and safety of medicinal therapy.
205. Criteria of efficiency of treatment of chronic atrophic gastritis (type A) and safety of medicinal therapy.
206. Criteria of efficiency of treatment of chronic Helicobacter-associated gastritis (type B) and safety of medicinal therapy.
207. Criteria of efficiency of stomach ulcer treatment and safety of medicinal therapy.
208. Criteria of efficiency of duodenal ulcer treatment and safety of medicinal therapy.
209. Criteria of efficiency of chronic pancreatitis treatment and safety of medicinal therapy.
210. Criteria of efficiency of chronic hepatitis treatment and safety of medicinal therapy.
211. Criteria of efficiency of chronic cholecystitis treatment and safety of medicinal therapy.
212. Criteria of efficiency of portal hypertension treatment and safety of medicinal therapy.
213. Criteria of efficiency of cirrhosis treatment and safety of medicinal therapy.
214. Criteria of efficiency of cholelithiasis treatment and safety of medicinal therapy.
215. Criteria of efficiency of diabetes mellitus treatment and safety of medicinal therapy.
216. Criteria of efficiency of treatment of insulin-independent diabetes mellitus and safety of medicinal therapy.
217. Criteria of efficiency of hyperthyroidism treatment and safety of medicinal therapy.
218. Criteria of efficiency of hypothyroidism treatment and safety of medicinal therapy.
219. Criteria of efficiency of endemic goiter treatment and safety of medicinal therapy.
220. Criteria of efficiency of allergic rhinitis treatment and allergic conjunctivitis (pollinosis) and safety of medicinal therapy.
221. Criteria of efficiency of urticaria treatment and safety of medicinal therapy.
222. Criteria of efficiency of angioneurotic edema treatment and safety of medicinal therapy.
223. Criteria of efficiency of anaphylactic shock treatment and safety of medicinal therapy.
224. Criteria of efficiency of drug disease treatment and safety of medicinal therapy.

Acting Head of Department of Clinical Pharmacology
and Clinical Pharmacy, Professor

_____ Tetiana SAKHAROVA



THE CRITERIA OF STUDY ACTIVITY ASSESSMENT IN PRACTICAL CLASSES

of **Clinical Pharmacy and Pharmaceutical Care** for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program **Pharmacy**,
4 years 10 months of study, Language of Instruction — English,
groups **ФМ19(4,10Д)англ-01, 02, 03, 04, 05, 06, 07, 08**
(*spring semester, 2022-2023, module 1*)

Scale	Criteria	1.5-2.5	3-5
«5» excellent 90-100%	<ul style="list-style-type: none"> Tasks for self-study for the lesson are done full and correctly Answers to theoretical questions on the topic of the lesson are given correctly and clearly Practical tasks during the in-class work were carried out full and correctly Final test has done in within 90-100%. 	2.3-2.5	4.5-5
«4» very good 82-89%	<ul style="list-style-type: none"> Tasks for self-study for the lesson are done full and correctly Answers to theoretical questions on the topic of the lesson are given full with negligible error Practical tasks during the in-class work were carried out with negligible error Final test has done in within 82-89%. 	2.1-2.2	4.1-4.4
«4-» good 74-81%	<ul style="list-style-type: none"> Tasks for self-study for the lesson are done with negligible error Answers to theoretical questions on the topic of the lesson are given incomplete with error Practical tasks during the in-class work were carried out with negligible deviation Final test has done in within 74-81%. 	1.9-2.0	3.7-4
«3» satisfactory 64-73%	<ul style="list-style-type: none"> Tasks for self-study for the lesson are done with significant error Answers to theoretical questions on the topic of the lesson are given incomplete or with significant error Practical tasks during the in-class work were carried out with significant deviation Final test has done in within 64-73%. 	1.6-1.8	3.2-3.6
«3-» enough 60-63%	<ul style="list-style-type: none"> Tasks for self-study for the lesson are done partly with significant error Answers to theoretical questions on the topic of the lesson are given incomplete with significant error Practical tasks during the in-class work were carried out partly with significant deviation Final test has done in within 60-63%. 	1.5	3-3.1
«2» unsatisfactory 0-59%	<ul style="list-style-type: none"> Tasks for self-study for the lesson aren't done or are done incorrect Answers to theoretical questions on the topic of the lesson aren't given Practical tasks during the in-class work weren't carried out are done incorrect Final test has done in within 0-59% 	0-1.4	0-2.9



THE LEARNING SUCCESS ASSESSMENT SYSTEM IN PRACTICAL CLASSES

of **Clinical Pharmacy and Pharmaceutical Care** for 4th year of speciality
226 Pharmacy, Industrial Pharmacy educational program **Pharmacy**,
4 years 10 months of study, Language of Instruction — English,
groups **ФМ19(4,10Д)англ-01, 02, 03, 04 ,05, 06, 07, 08**
(spring semester, 2022-2023, module 1)

Credit – 4

Total hours – 120

Lectures – 18

Practical classes – 60

Self-directed learning – 42

Semester control (Module #1) - *CREDIT*

Nati onal	ECTS	Grade	Credit	Content module 50 points	Content module control 20 points	Current rating 30 points	1.5-2.5	3.0-5.0
5	A — excellent	90-100	credit	45-50	18-20	27-30	2.3-2.5	4.5-5
4	B — very good	82-89	credit	41-44.5	16.5-17.5	25-26.5	2.1-2.2	4.1-4.4
4-	C — good	74-81	credit	37-40.5	15-16	22.5-24.5	1.9-2.0	3.7-4
3	D — satisfactory	64-73	credit	32-36.5	13-14.5	19.5-22	1.6-1.8	3.2-3.6
3-	E — enough (satisfies the minimum criteria)	60-63	credit	30-31.5	12-12.5	18-19	1.5	3-3.1
2	F – unsatisfactory (with possibility of repeated pass)	35-59	no credit	17.5-29.5	7-11.5	10.5-17.5	0.9-1.4	1.8-2.9
no adm issio n	FX — unsatisfactory with an obligatory repeated course (additional work is necessary)	1-34	—	0-17	0-6.5	0-10	0-0.8	0-1.7